Annovis Bio, Inc.

NYSE:ANVS

Biotechnology

Healthcare
$1.21 +0.00%

+$0.00 today

Market cap
$51.64M
Beta
1.24
P/E (TTM)
-1.1
EPS (TTM)
-$1.47
52W Low $1.54High $5.50

Volume 1.35M

Average 1.08M

ANVS Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Annovis Bio, Inc.NYSE: ANVS

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income growth accelerates

Q1 FY2026 net income of $17.61M (cash outflow) rose 218.0% year over year, ahead of the +40.8% change in trailing-twelve-month net income. Sequentially, it rose 79.0% from the prior quarter. Over 3 fiscal years it compounded at +944.4% a year.

Context

  • Net income grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +218.0% holds above the trailing-twelve-month pace of +40.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$17.61M+79.0% QoQ
Last fiscal yearDec 2025
-$28.85B+17.3% YoY
LTMMar 2026
-$40.92M+40.8% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+218.0%——
1 year+17.3%——
3-year CAGR+944.4%——
5-year CAGR——
10-year CAGR——

Net Income history

USD · from the cash flow

Latest · FY2025
(28.85B) USD
Year-over-year change
-17.3%

Net Income vs competitors

How ANVS compares with its peers on the latest reported figures

  • ANVS's LTM Mar 2026 net income of $40.92M is the 3rd largest of the 6 companies compared; the peer median is $24.25M.
  • Its year-over-year change of +40.8% is the 4th highest of 5, against a peer median of +93.0%.
  • Over three fiscal years its annual growth of +944.4% compares with a peer median of +6.6%.
ANVS Competitors Peer median
Net Income for ANVS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PDSBPDS Biotechnology CorporationLTM Mar 2026$18.8B +53055.5%+845.2%—
CELUCelularity Inc.LTM Dec 2025$91.72M +58.4%—345.4%
ANVSAnnovis Bio, Inc.LTM Mar 2026$40.92M +40.8%+944.4%—
PYPDPolyPid Ltd.LTM Dec 2025$34.17M —-4.8%—
MAIAMAIA Biotechnology, Inc.LTM Mar 2026$24.25M +23.1%+12.4%—
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$11.31M +127.6%+0.9%32.2%
Peer median (excluding ANVS) $24.25M+93.0%+6.6%188.8%

Competitors are the stored peer set for ANVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(14.49M)(25.33M)(56.2M)(24.59B)(28.85B)
Depreciation & Amortization00000
Deferred Income Tax00000
Stock-Based Compensation4.7M9.15M4.63M3.84B1.8B
Change in Working Capital657.35K(1.14M)(228.6K)681.71K1.58M
Accounts Receivables00000
Inventory00000
Accounts Payables346.22K3.27M(2.67M)1.01M284.54K
Other Working Capital311.13K(4.41M)2.44M(331.43K)1.29M
Other Non-Cash Items0011.84M(1.14B)1.44B
Operating Cash Flow(9.13M)(17.31M)(39.97M)(21.89B)(25.62B)
Capital Expenditures00000
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow00000
Debt Repayment00000
Common Stock Issued46.65M4.61K16.89M18.67M34.6M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities95.1K0458.39K26.67B34.57B
Financing Cash Flow46.74M4.61K17.34M26.69B34.6B
Effect of Forex Changes00000
Net Change in Cash37.61M(17.31M)(22.62M)4.8B8.98B
Free Cash Flow(9.13M)(17.31M)(39.97M)(21.89B)(25.62B)

Annovis Bio, Inc.

NYSE:ANVS

Intrinsic Alpha fair value

Locked

Current Price

$1.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.